nach oben

International Journal of Hematology

Erschienen in:

01.10.2010 | Progress in Hematology

Congenital dyserythropoietic anemia

verfasst von: Takahiro Kamiya, Atsushi Manabe

Erschienen in: International Journal of Hematology | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Congenital dyserythropoietic anemias (CDAs) are a heterogeneous group of rare hereditary disorders of erythropoiesis characterized by morphologic abnormal erythroblasts in the bone marrow. Three types of the disease are known as type I, II and III, and the variant type of CDA and several minor subgroups of CDA have been also reported since the first classification. Recently, responsible genes for type I (CDAN1) and type II (SEC23B) have been identified and the molecular pathogenesis of the disease is currently being explored. Although CDAs rarely transform to myelodysplastic syndrome or leukemia, the disease is important to understand the mechanism of hemopoiesis in humans.

Crookston JH, Godwin TF, Wjk R, et al. Congenital dyserythropoietic anemia (abstract). XIth congress of the international society of haematology, Sydney: vol. 18; 1966.

Heimpel H, Wendt F, Klemm D, et al. Congenital dyserythropoietic anemia. Arch Klin Med. 1968;215:174–94.PubMed

Wickramasinghe SN, Wood WG. Advances in the understanding of the congenital dyserythropoietic anaemias. Br J Haematol. 2005;131:431–46.CrossRefPubMed

Bessler M, Mason PJ, Link DC. Inherited bone marrow failure syndrome. In: Orkin SH, Nathan DG, Ginsburg D, Look AT, Fisher DE, Lux SE, et al., editors. Hematology of infancy and childhood. 7th ed. Philadelphia: Saunders; 2009. p. 307–95.

Dgany O, Avidan N, Delaunay J, et al. Congenital dyserythropoietic anemia type I is caused by mutations in codanin-1. Am J Hum Genet. 2002;71:1467–74.CrossRefPubMed

Greiner TC, Burns CP, Dick FR, et al. Congenital dyserythropoietic anemia type II diagnosed in a 69-year-old patient with iron overload. Am J Clin Pathol. 1992;98:522–5.PubMed

Iolascon A, Delaunay J, Wickramasinghe SN, et al. Natural history of congenital dyserythropoietic anemia type II. Blood. 2001;98(4):1258–60.CrossRefPubMed

Heimpel H. Congenital dyserythropoietic anemias: epidemiology, clinical significance, and progress in understanding their pathogenesis. Ann Hematol. 2004;83:613–21.CrossRefPubMed

Renella R, Wood WG. The congenital dyserythropoietic anemias. Hematol Oncol Clin N Am. 2009;23:283–306.CrossRef

10.

Heimpel H, Anselstetter V, Chrobak L, et al. Congenital dyserythropoietic anemia type II: epidemiology, clinical appearance, and prognosis based on long-term observation. Blood. 2003;102:4576–5581.CrossRefPubMed

11.

Lavabre-Bertrand T, Blanc P, Navarro R, et al. Alpha-interferon therapy for congenital dyserythropoietic anemia type I. Br J Haematol. 1995;89(4):929–32.CrossRefPubMed

12.

Shamseddine A, Taher A, Jaafar H, et al. Interferon alpha is an effective therapy for congenital dyserythropoietic anemia type I. Eur J Haematol. 2000;65:207–9.CrossRefPubMed

13.

Lavabre-Bertrand T, Ramos J, Delfour C, et al. Long-term alpha interferon treatment is effective ON anemia and significantly reduces iron overload in congenital dyserythropoiesis type I. Eur J Haematol. 2004;73:380–3.CrossRefPubMed

14.

Marwaha RK, Bansal D, Trehan A, et al. Interferon therapy in congenital dyserythropoietic anemia type I/II. Pediatr Hematol Oncol. 2005;22:133–8.CrossRefPubMed

15.

Goede JS, Benz R, Fehr J, et al. Congenital dyserythropoietic anemia type I with bone abnormalities, mutations of the CDAN I gene, and significant responsiveness to alpha-interferon therapy. Ann Hematol. 2006;85:591–5.CrossRefPubMed

16.

Ayas M, al-Jefri A, Baothman A, et al. Transfusion-dependent congenital dyserythropoietic anemia type I successfully treated with allogenic stem cell transplantation. Bone Marrow Transplant. 2002;29:681–2.CrossRefPubMed

17.

Iolascon A, Sabato V, de Mattia D, et al. Bone marrow transplantation in a case of severe, type II congenital dyserythropoietic anaemia (CDA II). Bone Marrow Transplant. 2001;27:213–5.CrossRefPubMed

18.

Remacha AF, Badell I, Pujoi-Moix N, et al. Hydrops fetalis-associated congenital dyserythropoietic anemia treated with intrauterine transfusions and bone marrow transplantation. Blood. 2002;100:356–8.CrossRefPubMed

19.

Heimpel H, Schwarz K, Ebnother M, et al. Congenital dyserythropoietic anemia type I (CDA I): molecular genetics, clinical appearance, and prognosis based on long-term observation. Blood. 2006;107:334–40.CrossRefPubMed

20.

Shalev H, Kapelushnik J, Moser A, et al. A comprehensive study of the neonatal manifestations of congenital dyserythropoietic anemia type I. J Pediatr Hematol Oncol. 2004;26:746–8.CrossRefPubMed

21.

Parez N, Dommergues M, Zupan V, et al. Severe congenital dyserythropoietic anaemia type I: prenatal management, transfusion support and alpha-interferon therapy. Br J Haematol. 2000;110:420–3.CrossRefPubMed

22.

Shalev H, Kapleushnik Y, Haeskelzon L, et al. Clinical and laboratory manifestations of congenital dyserythropoietic anemia type I in young adults. Eur J Haematol. 2002;68:170–4.CrossRefPubMed

23.

Wickramasinghe SN, Thein SL, Srichairatanakool S, Porter JB. Determinants of iron status and bilirubin levels in congenital dyserythropoietic anaemia type I. Br J Haematol. 1999;107(3):522–5.CrossRefPubMed

24.

Papanikolaou G, Tzilianos M, Christakis JI, et al. Hepcidin in iron overload disorders. Blood. 2005;105:4103–5.CrossRefPubMed

25.

Bader-Meunier B, Leverger G, Tchernia G, et al. Clinical and laboratory manifestations of congenital dyserythropoietic anemia type I in a cohort of French children. J Pediatr Hematol Oncol. 2005;27:416–9.CrossRefPubMed

26.

Wickramasinghe SN, Pippard MJ. Studies of erythroblast function in congenital dyserythropoietic anaemia, type I: evidence of impaired DNA, RNA, and protein synthesis and unbalanced globin chain synthesis in ultrastructurally abnormal cells. J Clin Pathol. 1986;39:881–90.CrossRefPubMed

27.

Jean R, Dossa D, Navarro M, et al. Congenital aplastic anemia, type I. Arch Fr Pediatr. 1975;32:337–48.PubMed

28.

Heimpel H, Forteza-Vila J, Queisser W, Spiertz E. Electron and light microscopic study of the erythroblasts of patients with congenital dyserythropoietic anemia. Blood. 1971;37:299–310.PubMed

29.

Alloisio N, Jaccoud P, Dorleac E, et al. Alterations of globin chain synthesis and of red cell membrane proteins in congenital dyserythropoietic anemia I and II. Pediatr Res. 1982;16:1016–21.CrossRefPubMed

30.

Tamary H, Shalmon L, Shalev H, et al. Localization of the gene for congenital dyserythropoietic anemia type I to a <1-cM interval on chromosome 15q15.1–15.3. Am J Hum Genet. 1998;62:1062–9.CrossRefPubMed

31.

Tamary H, Dgany O, Proust A, et al. Clinical and molecular variability in congenital dyserythropoietic anaemia type I. Br J Haematol. 2005;130:628–34.CrossRefPubMed

32.

Iolascon A, Delaunay J. Close to unraveling the secrets of congenital dyserythropoietic anemia type I and II. Haematologica. 2009;94:599–602.CrossRefPubMed

33.

Noy-Lotan S, Dgany O, Lahmi R, et al. Codanin-1, the protein encoded by the gene mutated in congenital dyserythropoietic anemia type I (CDAN1) is cell cycle-regulated. Haematologica. 2009;94:629–37.CrossRefPubMed

34.

Perrotta S, del Giudice EM, Carbone R, et al. Gilbert’s syndrome accounts for the phenotypic variability of congenital dyserythropoietic anemia type II (CDA-II). J Pediatr. 2000;136:556–9.CrossRefPubMed

35.

Gasparini P, Miraglia del Giudice E, Delaunay J, et al. Localization of the congenital dyserythropoietic anemia II locus to chromosome 20q11.2 by genome wide search. Am J Hum Genet. 1997;61:1112–6.CrossRefPubMed

36.

Lanzara C, Ficarella R, Totaro A, et al. Congenital dyserythropoietic anemia type II: exclusion of seven candidate genes. Blood Cells Mol Dis. 2003;30:22–9.CrossRefPubMed

37.

Schwarz K, Iolascon A, Verissimo F, et al. Mutations affecting the secretory COPII coat component SEC23B cause congenital dyserythropoietic anemia type II. Nat Genet. 2009;41:936–40.CrossRefPubMed

38.

Jones B, Jones EL, Bonney SA, et al. Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders. Nat Genet. 2003;34:29–31.CrossRefPubMed

39.

Boyadjiev SA, Fromme JC, Ben J, et al. Cranio-lenticulo-sutural dysplasia is caused by a SEC23A mutation leading to abnormal endoplasmic-reticulum-to-Golgi trafficking. Nat Genet. 2006;38:1192–7.CrossRefPubMed

40.

Iolascon A, Russo R, Esposito MR, et al. Molecular analysis of 42 patients with congenital dyserythropoietic anemia type II: new mutations in the SEC23B gene and a search for a genotype–phenotype relationship. Haematologica. 2010;95:708–15.CrossRefPubMed

41.

Sandstorm H, Wahlin A. Congenital dyserythropoietic anemia type III. Haematologica. 2000;85:737–57.

42.

Wolff JA, Von Hofe FH. Familial erythroid multinuclearity. Blood. 1951;6:1274–83.PubMed

43.

Bergstorm I, Jacobsson L. Hereditary benign erythroreticulosis. Blood. 1962;19:296–303.

44.

Lind L, Sandstorm H, Wahlin A, et al. Localization of the gene for congenital dyserythropoietic anemia type III, CDAN3, to chromosome 15q21–q25. Hum Mol Genet. 1995;4:109–12.CrossRefPubMed

45.

Sandstorm H, Wahlin A, Eriksson M, et al. Intravascular haemolysis and increased prevalence of myeloma and monoclonal gammopathy in congenital dyserythropoietic anemia, type III. Eur J Haematol. 1994;52:42–6.CrossRef

46.

Byrnes RK, Dhru R, Brady AM, et al. Congenital dyserythropoietic anemia in treated Hodgkin’s disease. Hum Pathol. 1980;11:485–6.CrossRefPubMed

47.

McCluggage WG, Hull D, Mayne E, et al. Malignant lymphoma in congenital dyserythropoietic anaemia type III. J Clin Pathol. 1996;49:599–602.CrossRefPubMed

48.

Wickramasinghe SN, Parry TE, Williams C, et al. A new case of congenital dyserythropoietic anaemia, type III: studied of the cell cycle distribution and ultrastructure of erythroblasts and of nucleic acid synthesis in marrow cells. J Clin Pathol. 1982;35:1103–9.CrossRefPubMed

49.

Wickramasinghe SN, Wahlin A, Anstee D, et al. Observations on two members of the Swedish family with congenital dyserythropoietic anaemia, type III. Eur J Haematol. 1993;50:213–21.CrossRefPubMed

50.

Nichols KE, Crispino JD, Poncz M, et al. Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nat Genet. 2000;24:266–70.CrossRefPubMed

51.

Taga T, Itoh T, Asami K, et al. Congenital dyserythropoietic anemia in Japanese children. Jpn J Pediatr Hematol. 2008;22:233–8 (in Japanese).

Titel: Congenital dyserythropoietic anemia
verfasst von: Takahiro Kamiya
Atsushi Manabe
Publikationsdatum: 01.10.2010
Verlag: Springer Japan
Erschienen in: International Journal of Hematology / Ausgabe 3/2010
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-010-0667-9

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Springer Medizin

Congenital dyserythropoietic anemia

Abstract

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma

Molecular pathogenesis in Diamond–Blackfan anemia

Hemorrhagic colonic ulcers caused by dasatinib for chronic myelogenous leukemia

Thiamine-responsive megaloblastic anemia syndrome

Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study

Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie